Emcure Pharmaceuticals Ltd.

Emcure soars on getting nod to market Poviztra for treatment of non-cirrhotic MASH

The approval enables Emcure to offer the new indication through Poviztra, expanding access to innovator semaglutide for patients living with a progressive liver disease

Emcure gets nod to market Poviztra for treatment of non-cirrhotic MASH

The approval enables Emcure to offer the new indication through Poviztra, expanding access to innovator semaglutide for patients living with a progressive liver disease

Emcure Pharmaceuticals rises on inking pact to acquire remaining 12.05% stake in Gennova

The Gennova will become a wholly-owned subsidiary of the company after completion of the transaction

Emcure Pharmaceuticals to acquire remaining 12.05% stake in Gennova

The Gennova will become a wholly-owned subsidiary of the company after completion of the transaction

Emcure Pharmaceuticals informs about acquisition

Emcure Pharmaceuticals informs about investor presentation

Kotak Mahindra Mutual Fund buys stake worth Rs 612 crore in Emcure Pharmaceuticals

Kotak Mahindra Mutual Fund has bought 36 lakh equity shares at price of Rs 1,700 apiece

USFDA concludes cGMP inspection at Emcure Pharmaceuticals’ Gujarat facility

At the conclusion of the inspection, the company was issued a Form 483 with 7 observation(s)

Emcure Pharma reports Profit after tax of Rs 2336.97 Mln, in the March 2026 quarter